Stoke Therapeutics Prepares to Defend Its Pipeline Narrative, But Zorevunersen Data Timing Looms Large

Stoke Therapeutics (STOK) reports second-quarter 2026 earnings after market close on August 3, with analysts expecting a loss of $0.82 per share. The central question for investors is whether the clinical-stage biotech can demonstrate progress on its lead candidate zorevunersen for Dravet syndrome while managing cash burn, as the company navigates a critical period between Phase III data readouts and potential commercialization.

Part 1: Earnings Preview

Stoke Therapeutics is a clinical-stage biotechnology company focused on developing antisense oligonucleotide (ASO) medicines to treat severe genetic diseases by upregulating protein expression. The company's lead candidate, zorevunersen, targets Dravet syndrome, a rare and severe form of epilepsy, with additional programs addressing other genetic disorders through its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform.

STOK is scheduled to report second-quarter 2026 results after market close on August 3, 2026. Analysts expect a loss of $0.82 per share on minimal revenue. The company most recently reported a loss of $0.79 per share for the first quarter of 2026, narrowly beating the $0.80 consensus estimate by 1.25%. Year-over-year, the expected loss of $0.82 represents a significant deterioration from the $0.40 loss reported in the second quarter of 2025, reflecting a 105% increase in losses as the company ramps up clinical development spending.

Three key themes define this earnings story:

Clinical Progress on Zorevunersen: Investors will scrutinize any updates on the Phase III program for zorevunersen in Dravet syndrome, including enrollment progress, timeline expectations, and any emerging long-term safety or efficacy data. The company's entire valuation thesis hinges on successful development and eventual commercialization of this lead asset.

Cash Runway and Burn Rate: With the company maintaining a cash position exceeding $400 million as of the most recent quarter, investors will focus on quarterly cash burn and updated guidance on how long current resources can fund operations. The widening losses underscore the importance of capital efficiency as STOK advances toward potential regulatory milestones.

Revenue Generation Challenges: The first quarter saw revenue of just $6.23 million miss estimates of $7.07 million by nearly 12%, highlighting ongoing challenges in generating meaningful top-line growth during the clinical development phase. Any commentary on collaboration revenue or milestone payments will be closely watched.

Analyst commentary ahead of the release reflects cautious optimism tempered by near-term execution concerns. While the Street maintains a strongly bullish stance with 12 Strong Buy ratings, the technical picture has deteriorated sharply, with Barchart's opinion shifting from an 8% Buy signal a month ago to an 88% Sell signal currently, suggesting mounting pressure on the stock as earnings approach.

Part 2: Historical Earnings Performance

Stoke Therapeutics has delivered a mixed earnings track record over the past four quarters, with two beats and two misses against analyst estimates. The company beat expectations by 29.82% in Q2 2025 (reporting -$0.40 versus -$0.57 estimated) and narrowly beat by 1.25% in Q1 2026 (reporting -$0.79 versus -$0.80 estimated). However, STOK missed estimates by 20.37% in Q3 2025 and by 29.33% in Q4 2025, the latter representing the largest miss in the recent period.

The pattern reveals significant volatility in the company's ability to meet expectations, with no clear directional trend. The magnitude of surprises has ranged from substantial beats to meaningful misses, suggesting challenges in forecasting expenses and revenue timing during this clinical development phase. The most recent quarter's narrow beat suggests improved alignment between management guidance and analyst models, though the upcoming quarter's 105% year-over-year increase in expected losses indicates accelerating investment in clinical programs that could introduce renewed forecasting uncertainty.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Stoke Therapeutics typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price behavior around STOK earnings shows substantial volatility, with an average absolute Day 0 move of 2.82% and Day +1 move of 6.33%. The most dramatic reaction came following the August 2025 report, when the stock surged 24.98% on Day +1 after beating estimates. Conversely, the November 2025 report triggered a 9.94% decline on Day +1 despite a relatively modest Day 0 move. The average Day 0 range of 7.96% and Day +1 range of 10.42% underscore the high-stakes nature of these releases for a clinical-stage biotech, where updates on drug development can drive outsized moves. Investors should prepare for potential double-digit percentage swings in either direction following the August 3 report.

Part 2.2: Options Market Expected Move

The options market is pricing an 11.49% expected move for STOK through the August 21 expiration, implying a range of $25.54 to $32.17. This expected move is notably higher than the historical average Day +1 move of 6.33%, suggesting options traders are anticipating above-average volatility for this particular release, possibly reflecting heightened uncertainty around clinical updates or cash burn guidance.

Part 3: What Analysts Are Saying

Analysts maintain a strongly bullish stance on Stoke Therapeutics, with the consensus rating at 4.79 out of 5.0 — firmly in Strong Buy territory. The current breakdown shows 12 Strong Buy ratings, 1 Moderate Buy, and 1 Hold, with zero sell-side recommendations. This represents an improved sentiment trend, as the Strong Buy count increased from 11 to 12 over the past month while the overall rating ticked up from 4.77.

The average price target of $45.79 implies substantial 58.6% upside from the current price of $28.86, with individual targets ranging from a low of $35.00 to a high of $60.00. The wide target range reflects differing views on the probability and timeline for zorevunersen's commercial success, though even the most conservative target suggests meaningful appreciation potential. The strengthening consensus and rising Strong Buy count indicate growing analyst confidence in STOK's clinical pipeline and commercial prospects, despite the near-term losses expected to continue through 2026 and 2027.

Part 4: Technical Picture

Stoke Therapeutics enters earnings with a deteriorating technical picture that stands in stark contrast to the bullish analyst consensus. The Barchart Technical Opinion has shifted dramatically from an 8% Buy signal one month ago to an 88% Sell signal currently, with the weakness accelerating over the past week from a 72% Sell reading. This sharp reversal suggests mounting technical pressure as the stock approaches its earnings release.

Timeframe Analysis:

• Short-term (100% Sell): Maximum bearish signal indicates severe near-term downward momentum heading into the report
• Medium-term (100% Sell): Continued sell signal across the intermediate timeframe confirms the weakness is not just a short-term phenomenon
• Long-term (50% Sell): Moderate sell signal suggests the longer-term trend has also turned negative, though with less intensity than shorter timeframes

Trend Characteristics: The combination of Soft strength and Strongest direction indicates a persistent but not yet extreme downtrend that is accelerating as earnings approach.

The stock is trading at $28.86, below all major moving averages: the 5-day ($29.42), 10-day ($29.15), 20-day ($30.02), 50-day ($30.31), 100-day ($31.96), and 200-day ($31.66). This complete breakdown below key technical levels signals broad-based selling pressure across all timeframes.

The 200-day moving average at $31.66 represents overhead resistance approximately 9.7% above current levels, while the stock's position below all shorter-term averages suggests no immediate technical support until substantially lower levels. The uniformly bearish technical setup, combined with the options market pricing an 11.49% expected move, creates a challenging environment heading into earnings. Investors should note that while fundamentals and analyst sentiment remain constructive, the technical deterioration suggests the market is pricing in execution risk or disappointment, making the actual results and forward guidance even more critical for determining whether the stock can stabilize or faces further downside pressure.